Rachel E Sanborn

23PUBLICATIONS
173CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Apr 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

|Feb 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.

Jong Chul Park, David Berz, Manish R Sharma

|Jan 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.

Jong Chul Park, David Berz, Manish R Sharma

|Dec 04, 2025
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.

Noboru Yamamoto, Dong Yan, Vinod Ganju

|Oct 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.

Melissa L Johnson, Egbert F Smit, Enriqueta Felip

|Jun 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.

Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu

Pageof 4

Frequent Collaborators

4 joint publications

Alexander I Spira

3 joint publications

Egbert F Smit

3 joint publications

Marcelo V Negrao

3 joint publications

Joshua Sabari